6054567

BEST AVAILABLE COPY



FIG. 1


1
2
3
MW
kD
221.2
105.7
74.7
46.3
29.6
18.6

FIG. 2A


1
2
3
MW
kD
221.2
105.7
74.7
46.3
29.6
18.6

FIG. 2B



FIG. 3A-1

FIG. 3A-2



FIG. 3A-3



FIG. 3A-4

FIG. 3B



FIG. 4A FIG. 4B FIG. 4C FIG. 4D


Chimp–1374 Anti–IgG
405 nm
0.8
0.6
0.4
0.2
0
120
100
80
60
40
20
0
ATL U/L
0 6 13 20 27 34 41 48 55 62 69 76 83 90 97 104
day post–inoculation
serum dilutions
1:20
1:400
1:8000

FIG. 5A


Chimp–1374 Anti–IgM
A 405 nm
1.5
1
0.5
0
ATL U/L
120
100
80
60
40
20
0 6 13 20 27 34 41 48 55 62 69 76 83 90 97 104
day post–inoculation
serum dilutions
1:20
1:400
1:8000

FIG. 5B


Chimp-1375 Anti-IgG
405 nm
ATL U/L
1.5
1
0.5
0
100
80
60
40
20
0 6 13 20 27 34 41 48 55 62 69 76 83 90 97 104
day post-inoculation
serum dilutions 1:20 1:400 1:8000

FIG. 5C


Chimp–1375 Anti–IgM
A 405 nm
ATL U/L
1.5
1
0.5
0
100
80
60
40
20
0 6 13 20 27 34 41 48 55 62 69 76 83 90 97 104
day post–inoculation
serum dilutions
1:20
1:400
1:8000

FIG. 5D


Cyno–377 (10^{-1})
A 405 nm
1.5
1
0.5
0
270
220
170
120
70
20
ATL U/L
0 7 14 22 29 36 43 50 57 64 71 78 83 92 99 104
day post–inoculation
serum dilutions
1:20
1:400
1:8000

FIG. 6A


Cyno-378 (10^{-1})
A 405 nm
1.5
1
0.5
0
270
220
170
120
70
20
ATL U/L
0 7 14 22 29 36 43 50 57 64 71 78 83 92 99 107
day post-inoculation
serum dilutions
1:20
1:400
1:8000

FIG. 6B


Cyno-395 (10^{-2})
A 405 nm
1.5
1
0.5
0
320
270
220
170
120
70
20
ATL U/L
0 6 14 19 26 32 39 49 55 62 69 77 83 97 112 126
− − − + + + + + B − − − − − − − −
day post-inoculation
serum dilutions
1:20
1:400
1:8000

FIG. 6C


Cyno-395 (10^{-2})
A 405 nm
1.5
1
0.5
0
320
270
220
170
120
70
20
ATL U/L
0 6 14 19 26 32 39 49 55 62 69 77 83 97 112 126
− − − + + − − − − − − − − − − −
day post-inoculation
serum dilutions
1:20
1:400
1:8000

FIG. 6D


Cyno-380 (10^{-3})
A 405 nm
1.5
1
0.5
0
140
120
100
80
60
70
20
ATL U/L
0 7 13 21 35 42 49 56 63 70 77 84 91 98 106 111
day post-inoculation
serum dilutions
1:20
1:400
1:8000

FIG. 6E


Cyno-383 (10^{-3})
A 405 nm
ATL U/L
1.5
1
0.5
0
80
70
60
50
40
30
20
0
7
14
22
29
36
43
50
57
64
71
78
83
92
99
107
day post-inoculation
serum dilutions
1:20
1:400
1:8000

FIG. 6F


Cyno–389 (10^{-4})
A 405 nm
ALT U/L
1.5
1
0.5
0
120
100
80
60
40
20
0 6 14 19 26 32 39 49 55 62 69 77 83 97 112 126
– – – – – + + + + + – – – – – –
day post–inoculation
serum dilutions
1:20
1:400
1:8000

FIG. 6G


Cyno-393(10^{-4})
A 405 nm
ALT U/L
1.5
1
0.5
0
100
80
60
40
20
0 6 14 19 26 32 39 49 55 62 69 77 83 97 112 126
day post-inoculation
serum dilutions
1:20
1:400
1:8000

FIG. 6H


Cyno-386 (10^{-5})
A 405 nm
ATL U/L
1.5
1
0.5
0
100
80
60
40
20
0
0 7 22 29 36 43 50 57 64 71 78 83 92 99 107 112
day post-inoculation
serum dilutions
1:20
1:400
1:8000

FIG. 6I


Cyno-385 (10^{-5})
A 405 nm
ATL U/L
1.5
1
0.5
0
100
80
60
40
20
0 7 21 28 35 42 49 56 63 70 77 84 91 98 106 111
− − + + +
day post-inoculation
serum dilutions
1:20
1:400
1:8000

FIG. 6J



FIG. 7A



FIG. 7B



FIG. 7C



FIG. 7D



FIG. 7E



FIG. 7F


cyno-389 anti-HEV IgG (10^{-4})
A 405 nm
ALT (U/L)
3
2.4
1.8
1.2
0.6
0
300
250
200
150
100
50
0
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
week post-inoculation

FIG. 7G


cyno-393 anti-HEV IgG (10^{-4})
A 405 nm
ALT (U/L)
3
2.4
1.8
1.2
0.6
0
300
250
200
150
100
50
0
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
week post-inoculation
GST
SG3
3-2
55kDa
ALT

FIG. 7H


cyno-385 anti-HEV IgG (10^{-5})
A 405 nm
ALT (U/L)
3
2.4
1.8
1.2
0.6
0
300
250
200
150
100
50
0
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
week post-inoculation

FIG. 7I


cyno-386 anti-HEV IgG (10^{-5})
A 405 nm
ALT (U/L)
3
2.4
1.8
1.2
0.6
0
300
250
200
150
100
50
0
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
week post-inoculation
GST SG3 3-2 55kDa ALT

FIG. 7J



FIG. 8A



FIG. 8B



FIG. 8C


cyno-389 anti-HEV IgM (10^{-4})
A 405 nm
ALT (U/L)
week post-inoculation
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
0 0.2 0.4 0.6 0.8 1
0 50 100 150 200 250 300

FIG. 8D


cyno-386 anti-HEV IgM (10^{-5})
A 405 nm
ALT (U/L)
week post-inoculation
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
0 0.2 0.4 0.6 0.8 1
0 50 100 150 200 250 300
GST SG3 3-2 55kDa ALT

FIG. 8E


M
10-1
10-2
10-3
10-4
10-5
10-6
6600
2300
2000
1353
1078
872
603
310
281, 271
234
194
118

FIG. 9



FIG. 10

RECEIVED


HEV GENOME
ORF 1
ORF 3
ORF 2
+1 aa
bHEV ORF2 fl
+660 aa
polh
promoter
+112 aa
bHEV ORF2 5' tr
+660 aa
polh
promoter
+112 aa
bHEV ORF2 5'-3' tr
+607 aa
polh
promoter

FIG. II

1 2 3 4 5 6 7 8 9 10 11 12



FIG. 12A

1 2 3 4 5 6 7 8 9 10 11 12



FIG. 12B


AU
0.00
0.05
0.10
0.15
0.20
0.25
0.00
20.00
40.00
60.00
80.00
100.00
120.00
140.00
160.00
Minutes

FIG. 13A


AU
0.00
0.20
0.40
0.60
0.80
1.00
1.20
0.00
10.00
20.00
30.00
40.00
50.00
60.00
70.00
80.00
Minutes

FIG. 13B


AU
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
0.16
0.00
10.00
20.00
30.00
40.00
50.00
60.00
70.00
Minutes

FIG. 13C

1 2 3 4 5 6 7 8 9 10 11 12

FIG. 14A

1 2 3 4 5 6 7 8 9 10 11 12

FIG. 14B


2
1.5
1
0.5
0
OD 215 nm
24
10
30
50
70
min

FIG. 15


Carboxypeptidase Y
125
100
75
50
25
0
pmol
0
5
15
30
60
90
120
O/N
min
L
S
V

FIG. 16



FIG. 17



FIG. 18A



FIG. 18B



FIG. 18C

RECEIVED



FIG. 18D

RECEIVED

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☑ FADED TEXT OR DRAWING
- ☑ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.
As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.